Status:
COMPLETED
An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer
Lead Sponsor:
Kathy Miller
Conditions:
Triple Negative Breast Cancer
Metastatic Breast Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
Phase 1 study to evaluate the safety and effect of Gedatolisib and PTK7-ADC for the treatment of triple negative breast cancer
Eligibility Criteria
Inclusion
- Metastatic Triple-negative Breast Cancer
- Willingness to undergo tumor biopsy
- Patients must have received at least 1 prior chemotherapy regimen for metastatic disease
Exclusion
- Previous treatment with mTOR inhibitor
- Untreated brain metastases
Key Trial Info
Start Date :
January 19 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 27 2020
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT03243331
Start Date
January 19 2018
End Date
May 27 2020
Last Update
January 7 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
IU Simon Cancer Center
Indianapolis, Indiana, United States, 46202